|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chemopreventive and Growth Inhibitory Effects of Selenium显示文摘There is very convincing evidence that a high dietary level of selenium substantially reduces the incidence of a wide variety of animal cancers. The human epidemiological evidence is less clear cut, but overall suggests that selenium may be protective: the evidence is strongest in men in relation to gastro-intestinal cancers. There is evidence that dietary selenium compounds reduce the formation of DNA adducts by carcinogens. Selenium compounds also inhibit growth in vitro and induce apoptosis. In general, there is a good correlation between the effectiveness of selenium compounds in chemoprevention and growth inhibition, implying that the mechanisms of growth inhibition and chemoprevention may be similar and that a major factor in the chemopreventive effects of selenium compounds in vivo is their ability to retard outgrowth of pre-malignant cells. Various hypotheses have been advanced as to how selenium compounds might prevent tumour cellgrowth. One is that they cause apoptosis by inducing oxidative stress. However, we have shown that the most potent selenium compound, selenodiglutathione (SDG), a natural metabolite of selenite, does not induce oxidative stress, at least not in the sarne way as other oxidants such as H2O2 and diamide. Firstly, a partially selenium-resistant variant cell line does not show increased resistance to H2O2. Moreover, SDG does not induce widespread tyrosine phosphorylation, including MAP and SAN kinases, like other oxidants such as H2O2 and diamide and its effects are not reversed by pretreatment with the tyrosine kinase inhibitor, herbimycin. Our experiments with the selenium-resistant variant suggest that a novel selenium-binding protein may be involved in growth inhibition by | P. R. HARRISON J. LANFEAR L. WU J. FLEMING L. MCGARRY, AND L. BLOWER (The Beatson Institute for Cancer Research, CRC Beatson Laboratories, Garscube Estate, Switchback Road,Bearsden, Glasgow, G61 1BD, Scotland, UK) | 1997 | Biomedical and Environmental Sciences1997，10，2： | 5 |
| 2 | Short and long term outcomes of 200 patients supported by continuous-flow left ventricular assist devices显示文摘AIM: To study the institutional experience over 8 years with 200 continuous-flow(CF)- left ventricular assist devices(LVAD).METHODS: We evaluated our institution's LVAD database and analyzed all patients who received a CF LVAD as a bridge to transplant(BTT) or destination therapy from March 2006 until June 2014. We identified 200 patients, of which 179 were implanted with a Heart Mate II device(Thoratec Corp., Pleasanton, CA) and 21 received a Heartware HVAD(Heart Ware Inc., Framingham, MA).RESULTS: The mean age of our LVAD recipients was 59.3 years(range 17-81), 76%(152/200) were males, and 49% were implanted for the indication of BTT. The survival rate for our LVAD patients at 30 d, 6 mo, 12 mo, 2 years, 3 years, and 4 years was 94%, 86%, 78%, 71%, 62% and 45% respectively. The mean duration of LVAD support was 581 d(range 2-2595 d). Gastrointestinal bleeding(was the most common adverse event(43/200, 21%), followed by right ventricular failure(38/200, 19%), stroke(31/200, 15%), re exploration for bleeding(31/200, 15%),ventilator dependent respiratory failure(19/200, 9%) and pneumonia(15/200, 7%). Our driveline infection rate was 7%. Pump thrombosis occurred in 6% of patients. Device exchanged was needed in 6% of patients. On multivariate analysis, preoperative liver dysfunction, ventilator dependent respiratory failure, tracheostomy and right ventricular failure requiring right ventricular assist device support were significant predictors of post LVAD survival.CONCLUSION: Short and long term survival for patients on LVAD support are excellent, although outcomes still remain inferior compared to heart transplantation. The incidence of driveline infections, pump thrombosis and pump exchange have declined significantly in recent years. | Athanasios Tsiouris Gaetano Paone Hassan W Nemeh Jamil Borgi Celeste T Williams David E Lanfear Jeffrey A Morgan | 2015 | World Journal of Cardiology2015，7，11： | 5 |
| 3 | Gastrointestinal bleeding with the HeartMate II left ventricular assist device显示文摘 | Jeffrey A. Morgan Gaetano Paone Hassan W. Nemeh Scott E. Henry Rosan Patel Jessica Vavra Celeste T. Williams David E. Lanfear Cristina Tita Robert J. Brewer | 2012 | Journal of Heart and Lung Transplantation2012，，7： | 2 |
| 4 | Genotype associated with myocardial infarction risk are more common in African Americans than in European Americans显示文摘 | David E Lanfear MD Sharon Marsh PHD | 2004 | J Am Coll Cardiol2004，44，： | 1 |
| 5 | Beta2-adrenergic receptor genotype and survival among patients receiving beat-blocker therapy after an acute coronary syndrome显示文摘 | Lanfear DE Jones PG Marsh S | 2005 | JAMA2005，294，12： | 1 |
| 6 | Genetic variation in the B-type natiuretic peptide pathway affects BNP levels显示文摘 | Lanfear DE Stolker JM Marsh S | 2007 | Cardiovasc Drugs Ther2007，21，1： | 1 |
| 7 | Genetic and Non-Genetic Factors Influencing Pharmacokinetics of B-type Natriuretic Peptide显示文摘 | Lanfear DE Chow S Padhiikasahasram B | 2014 | J Card Fail2014，28，： | 1 |
| 8 | Short term effects of milri- none on biomarkers of necrosis, apoptosis, and inflammation in pa- tients with severe heart failure显示文摘 | Lanfear DE Hasan R Gupta RC | 2009 | J Transl Meal2009，7，： | 1 |
| 9 | Clinical outcomes associatedwith proton pump inhibitor use among clopidogrel-treated patients withinCYP2C19 genotype groups following acute myocardial infarction显示文摘 | Depta JP Lenzini PA Lanfear DE | 2014 | Phar-macogenomics J2014，15，1： | 1 |
| 10 | Short term effects ofmilrinone on biomarkers of necrosis,apoptosis,and inflammation inpatients with severe heart failure显示文摘 | Lanfear DE Hasan R Gupta RC | 2009 | J Transl Med2009，67，7： | 1 |
| 11 | β2-adrenetgic receptor genotype and survival among patients receiving β-blocker therapy after an acute coronary syndrome显示文摘 | Lanfear DE Jones PG Marsh S | | 0，，： | 1 |
| 12 | Connexin37 (GJA4) genotype predicts survial after an acute coronary syndrome 显示文摘 | Lanfear DE Jones PG Marsh S | 2007 | Am Heart J2007，154，3： | 1 |
| 13 | Short term effects of milrinone on biomarkers of necrosis, apoptosis, and inflammation in patients with severe heart failure 显示文摘 | LANFEAR DE HASAN R GUPTA RC | 2009 | J Transl Med2009，7，： | 1 |
| 14 | The selenium metabolite selenodiglutathione induces p53 and apoptosis: relevance to the chemopreventive effects of selimium? 显示文摘 | Lanfear J Fleming J Wu LG | 1994 | Carcinogenesis1994，15，5： | 1 |
| 15 | Short term effects of milrinone on biomarkers of necrosis, apoptosis, andinflammation in patients with severe heart failure 显示文摘 | Lanfear DE Hasan R Gupta RC | 2009 | J Transl Med2009，7，： | 1 |
| 16 | Isolation and differential tissue dis tribution of two human cDNAs encoding PDEI splice variants显示文摘 | Fidock M Miller M Lanfear J | 2002 | Cell Signal2002，14，1： | 1 |
| 17 | Be- ta2-adrenergic receptor genotype and survival among patients receiving beat-blocker therapy after an acute coronary syndrome显示文摘 | LANFEAR D E JONES P G MARSH S | 2005 | JAMA2005，294，： | 1 |
| 18 | Diversification and the rate of molecular evolution: no evidence of a link in mammals 显示文摘 | Goldie X Lanfear R Bromham L | 2011 | BMC Evol Biol2011，11，1： | 1 |
| 19 | Genetic variation in the B-type natriuretic peptide pathway affects BNP levels显示文摘 | Lanfear D E Stolker J M Marsh S | 2007 | Cardiovasc Drugs Ther2007，21，1： | 1 |
| 20 | Mutation rate is linked to diversification in birds 显示文摘 | Lanfear R Ho SY Love D et ol | 2010 | Proc Natl Acad Sci USA2010，107，20： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员